Policy & Regulation
17 June 2024 - Immunotherapy company Northwest Biotherapeutics (OTCQB: NWBO) announced on Monday that it has secured an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio ...
17 June 2024 - Alternative asset management firm TPG (NASDAQ: TPG) declared on Monday that it has made a strategic investment in K2 Medical Research, an integrated clinical trial site platform special...
17 June 2024 - Immunotherapy company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) on Monday announced updated results from the Phase 1/2 trial of SAR443579/IPH6101 (SAR'579), a first-in-...
17 June 2024 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Monday that results from its Phase III trial ESLIM-01 of sovleplenib (HMPL-523) for p...
17 June 2024 - Immuno-oncology company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that Imfinzi (durvalumab), combined with carboplatin and paclitaxel followed by Imfinzi monot...
17 June 2024 - Commercial-stage pharmaceutical company Marinus Pharmaceuticals Inc (Nasdaq: MRNS) on Monday announced topline results from the Phase 3 RAISE trial evaluating the safety and efficacy of...